Page 1

abcam Abcam to Acquire BioVision for $ 340 million Released : 02 Aug 2021 07:00 RNS Number : 1621H ABCAM PLC 02 August 2021 Transaction highlights 2 August 2021 , Cambridge , UK - Abcam plc ( " Abcam " , " the Company " or " the Group " ) ( AIM LSE : ABC ; Nasdaq : ABCM ) , a global leader in the supply of life science research tools , today announces that it has entered into a definitive agreement to acquire BioVision , Inc. ( " BioVision " ) , a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. ( " NKY " ) , for $ 340 million ( the " Acquisition " ) . Abcam to Acquire BioVision for $ 340 million ABCAM PLC BioVision is a fast - growing innovator and distributor of life science research tools to biopharma , diagnostic and academic customers , with strength in biochemical and cell - based assay kits Brings one of Abcam's large third - party suppliers in - house Accelerates Abcam's strategic execution and focus on in - house innovation and products in the complementary biochemical and cell based assay market Background to and reasons for the Acquisition Expected to be accretive to earnings¹ from the first full year of ownership following completion ( Dec - 22 ) Concurrent with the Acquisition , entered memorandum of understanding regarding a strategic partnership with NKY in China Conference call scheduled for 1430 BST / 0930 EDT , today to discuss the transaction ● Founded in 1999 and located in Milpitas , California , BioVision is a global supplier of life science research tools to support research , diagnostics , and drug discovery . The company is a leading provider of biochemical and cell - based assays for biological research . It also develops , produces , and sells a wide portfolio of other products including recombinant proteins , antibodies , enzymes , and biochemical compounds . BioVision started supplying Abcam in 2003. Abcam customers ' demand for BioVision products has grown consistently over time , with sales more than doubling over the past five years ( to June 2021 ) . The acquisition of BioVision represents a compelling strategic fit for Abcam , with potential to : bring greater control over the innovation and distribution of BioVision's product portfolio accelerate our strategic ambitions within the adjacent biochemical and cellular assay market align with existing areas of research focus including oncology , immuno - oncology , neuroscience , and epigenetics create value through portfolio expansion and leveraging Abcam's global channels to market create opportunities to enhance existing products and innovate new products to serve customer needs Principal terms and financial effects of the Acquisition